Trading of Nifty 50 index futures on the Singapore stock exchange indicates that the Nifty could fall 10 points at the opening bell.

Overseas, Asian stocks fell after another tumble on Wall Street, where concerns have spread to the corporate-bond market. US stocks closed sharply lower Tuesday, extending a pre-Thanksgiving rout that has been fueled mostly by a selling in shares of technology and internet-related companies. US financial markets will be closed Thursday for the Thanksgiving Day holiday and see an early close Friday.

On the US data front, housing starts came in at a 1.228 million seasonally adjusted annual rate in October, while permits came in at a 1.263 million rate. Year-over-year, growth in housing starts has steadily slowed in 2018.

Back home, the market ended with sharp losses yesterday, 20 November 2018, snapping three sessions of gains, weighed by slide in index heavyweights HDFC, Infosys and Reliance Industries. The Sensex fell 300.37 points or 0.84% to settle at 35,474.51, its lowest closing level since 16 November 2018.

The trading activity on that day showed that the foreign portfolio investors (FPIs) sold shares worth a net Rs 753.17 crore yesterday, 20 November 2018, as per provisional data released by the stock exchanges. Domestic institutional investors (DIIs) sold shares worth a net Rs 44.06 crore yesterday, 20 November 2018, as per provisional data.

Among corporate news, Dr. Reddy's Laboratories announced favorable outcome in Buprenorphine and Naloxone Sublingual Film patent litigation. The United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy's Laboratories Inc., concluding that lndivior had not shown that it is likely to succeed on the merits of its infringement case on US Patent No. 9,931,305. This decision vacates the District Court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. As a result of the ruling, Dr. Reddy's will resume its launch activities as soon as permitted. The announcement was made after market hours yesterday, 20 November 2018.

In June, the US Food and Drug Administration (USFDA) approved Dr. Reddy's Buprenorphine and Naloxone Sublingual Film, in four strengths including 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, for sale in the US market. The product was launched immediately after approval, with sales and commercialization activites halted as a result of a court-imposted temporary restraining order (TRO) against Dr. Reddy's. The TRO did not include a prohibition on commercial manufacturing of the product.

Bank of Baroda has agreed to sell its 4% stake (20,00,000 equity shares) in The Clearing Corporation of India Limited (CCIL) to HDFC Bank as per share purchase agreement executed on 20 November 2018 at Rs 620 per share, aggregating to total consideration of Rs 124 crore. The announcement was made after market hours yesterday, 20 November 2018.